VERA Vera Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1831828 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-64.8%
TTM EPS YoY-47.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-113.5%
ROA-84.5%
ROIC (approx.)-87.8%
Asset turnover—
Leverage & solvency
Liabilities / assets28.5%
Debt / equity0.23x
Current ratio7.91x
Interest coverage-57.40x
Cash quality & payout
Operating cash flow / net income0.91x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $10.28M | — | — | — | $0 | — | — | — |
| Cost of revenue | $3.30M | — | — | — | $0 | — | — | — |
| Gross profit | $6.98M | — | — | — | $0 | — | — | — |
| R&D expense | $41.25M | $60.08M | $86.01M | $59.31M | $56.47M | $58.20M | $41.28M | $33.35M |
| SG&A expense | $61.43M | $52.41M | $39.12M | $34.90M | $27.46M | $21.95M | $15.92M | $15.57M |
| Operating income | -$95.70M | -$112.49M | -$125.13M | -$94.21M | -$83.93M | -$80.14M | -$57.19M | -$48.91M |
| Interest expense | $1.87M | $1.85M | $1.82M | $1.90M | $1.96M | $1.87M | $1.79M | $1.87M |
| Net income | -$93.71M | -$109.47M | -$121.03M | -$91.10M | -$80.29M | -$76.53M | -$51.69M | -$43.42M |
| EBITDA | -$94.88M | -$112.36M | -$124.99M | -$94.07M | -$83.80M | -$80.02M | -$57.11M | -$48.86M |
| EPS (basic) | -1.30 | -1.52 | -1.69 | — | -1.26 | -1.20 | -0.81 | — |
| EPS (diluted) | -1.30 | -1.52 | -1.69 | — | -1.26 | -1.20 | -0.81 | — |
| Weighted avg. shares (diluted) | 72.13M | 71.84M | 71.48M | — | 63.85M | 63.79M | 63.67M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $55.32M | $48.88M | $114.35M | $354.73M | $57.77M | $49.12M | $55.09M | $92.65M |
| Short-term investments | $328.72M | $450.29M | $482.41M | $359.86M | $439.62M | $507.71M | $534.74M | $548.21M |
| Receivables | $11.98M | — | — | $0 | — | — | — | — |
| Inventory | $7.08M | — | — | $0 | — | — | — | — |
| Current assets | $441.29M | $527.49M | $615.80M | $728.88M | $511.31M | $571.35M | $606.08M | $651.22M |
| PP&E, net | — | $813,000 | $945,000 | $1.37M | $1.16M | $1.15M | $1.06M | $960,000 |
| Intangibles | $20.50M | — | — | $0 | — | — | — | — |
| Total assets | $465.75M | $532.98M | $621.74M | $734.73M | $517.50M | $578.53M | $610.17M | $655.68M |
| Current liabilities | $55.77M | $48.32M | $45.15M | $53.45M | $41.88M | $33.55M | $21.89M | $25.37M |
| Long-term debt | $75.43M | $75.23M | $75.03M | $74.84M | $74.65M | $74.46M | $50.91M | $50.69M |
| Total debt | $75.43M | $75.23M | $75.03M | $74.84M | $74.65M | $74.46M | $50.91M | $50.69M |
| Total liabilities | $132.57M | $125.23M | $122.04M | $130.21M | $118.62M | $110.25M | $75.17M | $78.53M |
| Shareholders' equity | $333.19M | $407.76M | $499.70M | $604.52M | $398.88M | $468.28M | $535.00M | $577.15M |
| Net debt | $20.11M | $26.35M | -$39.32M | -$279.89M | $16.88M | $25.34M | -$4.18M | -$41.96M |
| Cash flow statement | ||||||||
| Operating cash flow | -$99.18M | -$100.25M | -$106.50M | -$69.99M | -$61.91M | -$54.80M | -$54.41M | -$39.18M |
| Capital expenditure | $0 | $0 | $23,000 | $102,000 | $133,000 | $208,000 | $187,000 | $645,000 |
| Free cash flow | -$99.18M | -$100.25M | -$106.52M | -$70.10M | -$62.04M | -$55.01M | -$54.59M | -$39.83M |
| Investing cash flow | $101.91M | $32.86M | -$137.82M | $80.66M | $69.76M | $28.54M | $15.32M | -$221.38M |
| Financing cash flow | $3.71M | $1.92M | $3.94M | $286.28M | $797,000 | $20.29M | $1.53M | $325.95M |
| Depreciation & amortization | $823,000 | $132,000 | $140,000 | $135,000 | $129,000 | $119,000 | $85,000 | $55,000 |
| Stock-based compensation | $15.73M | $15.86M | $13.21M | $10.96M | $9.74M | $9.47M | $7.74M | $6.22M |
| Share buybacks | — | — | — | $0 | — | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.